Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name FGFR1 positive
Gene Variant Detail

FGFR1 positive (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR1 positive leiomyosarcoma decreased response PD173074 Preclinical - Cell culture Actionable In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980). 27535980
FGFR1 positive uterus leiomyosarcoma decreased response PD173074 Preclinical - Cell culture Actionable In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980). 27535980
FGFR1 positive synovial sarcoma decreased response PD173074 Preclinical - Cell culture Actionable In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980). 27535980
FGFR1 positive leiomyosarcoma decreased response Fexagratinib Preclinical - Cell culture Actionable In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980). 27535980
FGFR1 positive uterus leiomyosarcoma decreased response Fexagratinib Preclinical - Cell culture Actionable In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980). 27535980
FGFR1 positive synovial sarcoma decreased response Fexagratinib Preclinical - Cell culture Actionable In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980). 27535980
FGFR1 positive leiomyosarcoma decreased response Infigratinib Preclinical - Cell culture Actionable In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to Truseltiq (infigratinib) in culture (PMID: 27535980). 27535980
FGFR1 positive uterus leiomyosarcoma decreased response Infigratinib Preclinical - Cell culture Actionable In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to Truseltiq (infigratinib) in culture (PMID: 27535980). 27535980
FGFR1 positive synovial sarcoma decreased response Infigratinib Preclinical - Cell culture Actionable In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to Truseltiq (infigratinib) in culture (PMID: 27535980). 27535980
FGFR1 positive lung adenocarcinoma sensitive AZD8055 + Fexagratinib Preclinical - Cell culture Actionable In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452). 26359452
FGFR1 positive lung large cell carcinoma sensitive AZD8055 + Fexagratinib Preclinical - Cell culture Actionable In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452). 26359452
FGFR1 positive lung large cell carcinoma sensitive Fexagratinib + Vistusertib Preclinical - Cell line xenograft Actionable In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture and in cell line xenograft models (PMID: 26359452). 26359452
FGFR1 positive lung adenocarcinoma sensitive Fexagratinib + Vistusertib Preclinical - Cell line xenograft Actionable In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture and in cell line xenograft models (PMID: 26359452). 26359452
FGFR1 positive head and neck squamous cell carcinoma sensitive Fexagratinib + Vistusertib Preclinical - Cell culture Actionable In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent head and neck squamous cell carcinoma cells in culture (PMID: 26359452). 26359452
FGFR1 positive lung adenocarcinoma sensitive Fexagratinib + Sirolimus Preclinical - Cell culture Actionable In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452). 26359452
FGFR1 positive lung large cell carcinoma sensitive Fexagratinib + Sirolimus Preclinical - Cell culture Actionable In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452). 26359452
FGFR1 positive salivary gland adenoid cystic carcinoma predicted - sensitive Rogaratinib Case Reports/Case Series Actionable In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial response in a patient with FGFR1-positive adenoid cystic carcinoma of the tongue (PMID: 31405822; NCT01976741). 31405822
FGFR1 positive hemangioma predicted - sensitive Rogaratinib Case Reports/Case Series Actionable In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease with resolution of edema in a patient with FGFR1-positive hemangioendothelioma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741). detail...
FGFR1 positive glioblastoma sensitive CYY292 Preclinical - Cell line xenograft Actionable In a preclinical study, CYY292 inhibited Fgfr1 downstream signaling, proliferation, migration, and invasion in Fgfr1-expressing glioblastoma cell lines in culture, inhibited tumor growth in a cell line xenograft model, and inhibited growth and improved survival in an orthotopic xenograft model of glioblastoma (PMID: 37588207). 37588207